Free Trial
NASDAQ:NXTC

NextCure (NXTC) Stock Price, News & Analysis

NextCure logo
$0.39 -0.01 (-1.74%)
Closing price 04/4/2025 04:00 PM Eastern
Extended Trading
$0.40 +0.01 (+2.79%)
As of 04/4/2025 07:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About NextCure Stock (NASDAQ:NXTC)

Key Stats

Today's Range
$0.37
$0.40
50-Day Range
$0.39
$0.81
52-Week Range
$0.35
$2.23
Volume
97,822 shs
Average Volume
91,761 shs
Market Capitalization
$10.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.50
Consensus Rating
Buy

Company Overview

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.

Remove Ads

NextCure Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
79th Percentile Overall Score

NXTC MarketRank™: 

NextCure scored higher than 79% of companies evaluated by MarketBeat, and ranked 185th out of 902 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    NextCure has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    NextCure has only been the subject of 1 research reports in the past 90 days.

  • Read more about NextCure's stock forecast and price target.
  • Earnings Growth

    Earnings for NextCure are expected to grow in the coming year, from ($1.87) to ($1.44) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of NextCure is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of NextCure is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    NextCure has a P/B Ratio of 0.10. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about NextCure's valuation and earnings.
  • Percentage of Shares Shorted

    0.30% of the float of NextCure has been sold short.
  • Short Interest Ratio / Days to Cover

    NextCure has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in NextCure has recently decreased by 2.52%, indicating that investor sentiment is improving.
  • Dividend Yield

    NextCure does not currently pay a dividend.

  • Dividend Growth

    NextCure does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.30% of the float of NextCure has been sold short.
  • Short Interest Ratio / Days to Cover

    NextCure has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in NextCure has recently decreased by 2.52%, indicating that investor sentiment is improving.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for NextCure this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, NextCure insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    13.30% of the stock of NextCure is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    42.65% of the stock of NextCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about NextCure's insider trading history.
Receive NXTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NextCure and its competitors with MarketBeat's FREE daily newsletter.

NXTC Stock News Headlines

FBI Warns: Wave Of Retiree Cyber Hacks Coming In 2025
Try to think back to the fall of 2008… The pandemic accelerated America's descent into a “no-cash society” by several years…
Piper Sandler Sticks to Its Buy Rating for NextCure (NXTC)
See More Headlines

NXTC Stock Analysis - Frequently Asked Questions

NextCure's stock was trading at $0.7710 at the start of the year. Since then, NXTC stock has decreased by 49.4% and is now trading at $0.3901.
View the best growth stocks for 2025 here
.

NextCure, Inc. (NASDAQ:NXTC) released its quarterly earnings data on Thursday, March, 6th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.34) by $0.07.

NextCure (NXTC) raised $75 million in an initial public offering on Thursday, May 9th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofAMerrill Lynch, Pierce and Piper Jaffray acted as the underwriters for the IPO.

Shares of NXTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that NextCure investors own include Waste Connections (WCN), DiamondRock Hospitality (DRH), The RMR Group (RMR), AUO (AUOTY), American Water Works (AWK), iShares Micro-Cap ETF (IWC) and Voyager Therapeutics (VYGR).

Company Calendar

Last Earnings
3/06/2025
Today
4/06/2025
Next Earnings (Estimated)
5/01/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:NXTC
Fax
N/A
Employees
90
Year Founded
2015

Price Target and Rating

Average Stock Price Target
$3.50
High Stock Price Target
$4.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+797.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-62,720,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$4.10 per share
Price / Book
0.10

Miscellaneous

Free Float
24,282,000
Market Cap
$10.93 million
Optionable
Optionable
Beta
0.89
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:NXTC) was last updated on 4/6/2025 by MarketBeat.com Staff
From Our Partners